Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02131662 · ClinicalTrials.gov registry record · Phase 2
Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 309
- Enrollment target
NCT02131662 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 309 participants.
The verdict
NCT02131662, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 309 participants
- Enrollment target
Study Summary
The study is performed to assess the efficacy and safety of different doses of BAY1002670 in subjects with uterine fibroids. The dose-response relationship will be evaluated. Further, the study aims to establish a population pharmacokinetic/pharmacodynamic relationship for BAY1002670 in subjects with uterine fibroids. To assess the efficacy of BAY1002670 the interchangeability of menstrual pictogram and alkaline hematin method for the judgement of menstrual blood loss will be assessed.
Interventions
- DRUG Placebo
- DRUG BAY1002670
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2014-05-15 |
| Est. Completion | 2016-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02131662
The ClinicalTrials.gov registry entry for NCT02131662 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 309 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02131662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02131662 about?
NCT02131662 is a clinical study titled "Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap". The study is performed to assess the efficacy and safety of different doses of BAY1002670 in subjects with uterine fibroids. The dose-response relationship will be evaluated. Further, the study aims to establish a population pharmacokinetic/pharmacodynamic relationship for BAY1002670 in subjects wit...
What is the current status of trial NCT02131662?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 309 participants. The study started on 2014-05-15. Estimated completion is 2016-05-04.
What interventions are being tested in trial NCT02131662?
The interventions under investigation include: Placebo (DRUG), BAY1002670 (DRUG).
Who is sponsoring clinical trial NCT02131662?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.